nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—DDC—nerve—skin cancer	0.0485	0.116	CbGeAlD
Droxidopa—ADRB3—connective tissue—skin cancer	0.0268	0.0638	CbGeAlD
Droxidopa—SLC6A2—nerve—skin cancer	0.0231	0.0551	CbGeAlD
Droxidopa—PAH—head—skin cancer	0.0202	0.0481	CbGeAlD
Droxidopa—SLC16A10—nipple—skin cancer	0.0189	0.045	CbGeAlD
Droxidopa—ADRB3—female reproductive system—skin cancer	0.0189	0.045	CbGeAlD
Droxidopa—SLC16A10—neck—skin cancer	0.0187	0.0446	CbGeAlD
Droxidopa—ADRA1D—epithelium—skin cancer	0.0143	0.0341	CbGeAlD
Droxidopa—DDC—female reproductive system—skin cancer	0.0138	0.0328	CbGeAlD
Droxidopa—SLC16A10—epithelium—skin cancer	0.0127	0.0303	CbGeAlD
Droxidopa—ADRA2C—nipple—skin cancer	0.0116	0.0277	CbGeAlD
Droxidopa—DDC—head—skin cancer	0.0115	0.0274	CbGeAlD
Droxidopa—SLC16A10—mammalian vulva—skin cancer	0.011	0.0263	CbGeAlD
Droxidopa—ADRB1—connective tissue—skin cancer	0.0109	0.0261	CbGeAlD
Droxidopa—ADRA1D—female reproductive system—skin cancer	0.0106	0.0253	CbGeAlD
Droxidopa—SLC16A10—lymphoid tissue—skin cancer	0.0098	0.0233	CbGeAlD
Droxidopa—SLC16A10—female reproductive system—skin cancer	0.00945	0.0225	CbGeAlD
Droxidopa—ADRA2A—nipple—skin cancer	0.00927	0.0221	CbGeAlD
Droxidopa—ADRA1B—head—skin cancer	0.00907	0.0216	CbGeAlD
Droxidopa—ADRA1D—head—skin cancer	0.00887	0.0212	CbGeAlD
Droxidopa—ADRA1A—epithelium—skin cancer	0.00821	0.0196	CbGeAlD
Droxidopa—DDC—lymph node—skin cancer	0.00806	0.0192	CbGeAlD
Droxidopa—ADRB1—female reproductive system—skin cancer	0.00772	0.0184	CbGeAlD
Droxidopa—ADRA2C—mammalian vulva—skin cancer	0.00679	0.0162	CbGeAlD
Droxidopa—ADRA2A—connective tissue—skin cancer	0.00658	0.0157	CbGeAlD
Droxidopa—SLC6A2—female reproductive system—skin cancer	0.00656	0.0156	CbGeAlD
Droxidopa—ADRB1—head—skin cancer	0.00645	0.0154	CbGeAlD
Droxidopa—ADRA1A—lymphoid tissue—skin cancer	0.00633	0.0151	CbGeAlD
Droxidopa—Aminosalicylic Acid—PTGS2—skin cancer	0.00587	0.561	CrCbGaD
Droxidopa—SLC16A10—lymph node—skin cancer	0.00553	0.0132	CbGeAlD
Droxidopa—SLC6A2—head—skin cancer	0.00548	0.0131	CbGeAlD
Droxidopa—ADRA2A—mammalian vulva—skin cancer	0.00542	0.0129	CbGeAlD
Droxidopa—ADRA1A—head—skin cancer	0.0051	0.0121	CbGeAlD
Droxidopa—ADRA2C—head—skin cancer	0.00486	0.0116	CbGeAlD
Droxidopa—ADRA2A—female reproductive system—skin cancer	0.00464	0.0111	CbGeAlD
Droxidopa—Mesalazine—PTGS2—skin cancer	0.00461	0.44	CrCbGaD
Droxidopa—ADRA2A—head—skin cancer	0.00388	0.00924	CbGeAlD
Droxidopa—SLC6A2—lymph node—skin cancer	0.00384	0.00915	CbGeAlD
Droxidopa—ADRA2C—lymph node—skin cancer	0.0034	0.00811	CbGeAlD
Droxidopa—ADRA2A—lymph node—skin cancer	0.00271	0.00647	CbGeAlD
Droxidopa—ADRB1—Signaling by GPCR—SMO—skin cancer	0.00052	0.000912	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—PTCH1—skin cancer	0.00052	0.000912	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—PTCH1—skin cancer	0.000517	0.000908	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—SMO—skin cancer	0.000517	0.000908	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—PTGER4—skin cancer	0.000516	0.000905	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—SMO—skin cancer	0.000515	0.000904	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—PTCH1—skin cancer	0.000515	0.000904	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PTCH2—skin cancer	0.000509	0.000893	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—PTCH1—skin cancer	0.000508	0.000892	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—SMO—skin cancer	0.000508	0.000892	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—PTGER4—skin cancer	0.000508	0.00089	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—SHH—skin cancer	0.000507	0.00089	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—PTGER4—skin cancer	0.000506	0.000888	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—PTGER4—skin cancer	0.000504	0.000884	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—PTGER4—skin cancer	0.000501	0.00088	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—SHH—skin cancer	0.000499	0.000876	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MC1R—skin cancer	0.000499	0.000875	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—PTGER4—skin cancer	0.000495	0.000868	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—GLI1—skin cancer	0.000492	0.000863	CbGpPWpGaD
Droxidopa—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000485	0.000851	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—PTCH1—skin cancer	0.000481	0.000844	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—SMO—skin cancer	0.000481	0.000844	CbGpPWpGaD
Droxidopa—DDC—Metabolism—ERCC2—skin cancer	0.000479	0.000841	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—GLI2—skin cancer	0.000476	0.000836	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—PTCH1—skin cancer	0.000473	0.000831	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—SMO—skin cancer	0.000473	0.000831	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PTCH2—skin cancer	0.000473	0.000829	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—GLI2—skin cancer	0.000472	0.000828	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—PTGER4—skin cancer	0.000468	0.000822	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000468	0.000821	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—GLI2—skin cancer	0.000466	0.000818	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—SUFU—skin cancer	0.000466	0.000818	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—PTGER4—skin cancer	0.000461	0.000809	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MC1R—skin cancer	0.000455	0.000797	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—PTGER4—skin cancer	0.000451	0.000791	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MC1R—skin cancer	0.00045	0.00079	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—GLI1—skin cancer	0.000448	0.000786	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—FOXO4—skin cancer	0.000445	0.00078	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MC1R—skin cancer	0.000445	0.00078	CbGpPWpGaD
Droxidopa—PAH—Metabolism—PTGS2—skin cancer	0.000444	0.00078	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—GLI1—skin cancer	0.000444	0.000779	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—SHH—skin cancer	0.000444	0.000778	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—GLI2—skin cancer	0.000441	0.000774	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—GLI1—skin cancer	0.000438	0.000769	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—GLI2—skin cancer	0.000434	0.000761	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CSPG4—skin cancer	0.000428	0.000752	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—SUFU—skin cancer	0.000425	0.000745	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—SUFU—skin cancer	0.000421	0.000738	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MC1R—skin cancer	0.000421	0.000738	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—PTCH1—skin cancer	0.000421	0.000738	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—SMO—skin cancer	0.000421	0.000738	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—PTGER4—skin cancer	0.000419	0.000735	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—SUFU—skin cancer	0.000415	0.000729	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000415	0.000729	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—GLI1—skin cancer	0.000415	0.000727	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MC1R—skin cancer	0.000414	0.000726	CbGpPWpGaD
Droxidopa—PAH—Disease—NRAS—skin cancer	0.000413	0.000724	CbGpPWpGaD
Droxidopa—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000412	0.000723	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—SHH—skin cancer	0.000412	0.000723	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—PTGER4—skin cancer	0.000409	0.000718	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—GLI1—skin cancer	0.000408	0.000716	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000403	0.000706	CbGpPWpGaD
Droxidopa—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000395	0.000692	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—SUFU—skin cancer	0.000393	0.00069	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—SMO—skin cancer	0.000391	0.000686	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—PTCH1—skin cancer	0.000391	0.000686	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—SUFU—skin cancer	0.000387	0.000679	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—GLI2—skin cancer	0.000386	0.000676	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—PTGER4—skin cancer	0.00038	0.000667	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MC1R—skin cancer	0.000368	0.000645	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—GLI1—skin cancer	0.000362	0.000636	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ENO2—skin cancer	0.000359	0.000629	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—GLI2—skin cancer	0.000358	0.000628	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000358	0.000627	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—SHH—skin cancer	0.000355	0.000624	CbGpPWpGaD
Droxidopa—PAH—Disease—KRAS—skin cancer	0.000355	0.000623	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RASA1—skin cancer	0.000353	0.00062	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SUFU—skin cancer	0.000344	0.000603	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000342	0.0006	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MC1R—skin cancer	0.000342	0.0006	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PTCH1—skin cancer	0.000337	0.000591	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—SMO—skin cancer	0.000337	0.000591	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—GLI1—skin cancer	0.000337	0.000591	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PTGER4—skin cancer	0.000328	0.000576	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000327	0.000575	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—SHH—skin cancer	0.000324	0.000568	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RASA1—skin cancer	0.000322	0.000565	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—SHH—skin cancer	0.000321	0.000563	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SUFU—skin cancer	0.000319	0.00056	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RASA1—skin cancer	0.000319	0.00056	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—SHH—skin cancer	0.000317	0.000556	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RASA1—skin cancer	0.000315	0.000552	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PTCH1—skin cancer	0.000307	0.000539	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—SMO—skin cancer	0.000307	0.000539	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PTCH1—skin cancer	0.000304	0.000534	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—SMO—skin cancer	0.000304	0.000534	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000304	0.000533	CbGpPWpGaD
Droxidopa—PAH—Disease—HRAS—skin cancer	0.000302	0.00053	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—SMO—skin cancer	0.0003	0.000527	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PTCH1—skin cancer	0.0003	0.000527	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—SHH—skin cancer	0.0003	0.000526	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PTGER4—skin cancer	0.000299	0.000524	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RASA1—skin cancer	0.000298	0.000523	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TERT—skin cancer	0.000297	0.000521	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PTGER4—skin cancer	0.000296	0.00052	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—SHH—skin cancer	0.000295	0.000518	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RASA1—skin cancer	0.000293	0.000514	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PTGER4—skin cancer	0.000292	0.000513	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ENO2—skin cancer	0.000291	0.000511	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000291	0.00051	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—FOXO4—skin cancer	0.00029	0.000508	CbGpPWpGaD
Droxidopa—PAH—Disease—IL6—skin cancer	0.000289	0.000507	CbGpPWpGaD
Droxidopa—DDC—Metabolism—PTGS2—skin cancer	0.000287	0.000504	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PTCH1—skin cancer	0.000284	0.000499	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—SMO—skin cancer	0.000284	0.000499	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PTCH1—skin cancer	0.00028	0.000491	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—SMO—skin cancer	0.00028	0.000491	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PTGER4—skin cancer	0.000277	0.000485	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PTGER4—skin cancer	0.000272	0.000478	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—FOXO4—skin cancer	0.000264	0.000463	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SHH—skin cancer	0.000262	0.00046	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—FOXO4—skin cancer	0.000262	0.000459	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RASA1—skin cancer	0.00026	0.000457	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—FOXO4—skin cancer	0.000258	0.000453	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—NRAS—skin cancer	0.000257	0.00045	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—NRAS—skin cancer	0.00025	0.000439	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PTCH1—skin cancer	0.000248	0.000436	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SMO—skin cancer	0.000248	0.000436	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—FOXO4—skin cancer	0.000244	0.000429	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SHH—skin cancer	0.000243	0.000427	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RASA1—skin cancer	0.000242	0.000425	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PTGER4—skin cancer	0.000242	0.000424	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—FOXO4—skin cancer	0.000241	0.000422	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—NRAS—skin cancer	0.00024	0.00042	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—BRAF—skin cancer	0.000235	0.000413	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PTCH1—skin cancer	0.000231	0.000405	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SMO—skin cancer	0.000231	0.000405	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PTGER4—skin cancer	0.000225	0.000394	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—KRAS—skin cancer	0.000221	0.000387	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—KRAS—skin cancer	0.000215	0.000378	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—FOXO4—skin cancer	0.000214	0.000375	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ERCC2—skin cancer	0.000208	0.000365	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—KRAS—skin cancer	0.000206	0.000362	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—FOXO4—skin cancer	0.000198	0.000348	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—TP53—skin cancer	0.000196	0.000344	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—NRAS—skin cancer	0.000195	0.000341	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TERT—skin cancer	0.000194	0.00034	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—HRAS—skin cancer	0.000188	0.000329	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—TP53—skin cancer	0.000183	0.000322	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—HRAS—skin cancer	0.000183	0.000321	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TERT—skin cancer	0.000176	0.000309	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—HRAS—skin cancer	0.000175	0.000308	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—IL6—skin cancer	0.000175	0.000308	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TERT—skin cancer	0.000175	0.000307	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TERT—skin cancer	0.000173	0.000303	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ERCC2—skin cancer	0.000169	0.000297	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—KRAS—skin cancer	0.000168	0.000294	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TERT—skin cancer	0.000163	0.000286	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—NRAS—skin cancer	0.000163	0.000286	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TERT—skin cancer	0.000161	0.000282	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—BRAF—skin cancer	0.000153	0.000269	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—TP53—skin cancer	0.000149	0.000261	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—NRAS—skin cancer	0.000149	0.000261	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—NRAS—skin cancer	0.000148	0.000259	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—NRAS—skin cancer	0.000147	0.000258	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—NRAS—skin cancer	0.000145	0.000255	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TERT—skin cancer	0.000143	0.00025	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—HRAS—skin cancer	0.000142	0.00025	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—KRAS—skin cancer	0.00014	0.000246	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—BRAF—skin cancer	0.00014	0.000245	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—BRAF—skin cancer	0.000138	0.000243	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—NRAS—skin cancer	0.000138	0.000241	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—BRAF—skin cancer	0.000137	0.00024	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—NRAS—skin cancer	0.000135	0.000237	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TERT—skin cancer	0.000133	0.000233	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—BRAF—skin cancer	0.000129	0.000227	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—KRAS—skin cancer	0.000128	0.000224	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—KRAS—skin cancer	0.000127	0.000223	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—BRAF—skin cancer	0.000127	0.000223	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—KRAS—skin cancer	0.000127	0.000222	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—KRAS—skin cancer	0.000125	0.000219	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTGS2—skin cancer	0.000125	0.000219	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—NRAS—skin cancer	0.00012	0.000211	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—HRAS—skin cancer	0.000119	0.000209	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—KRAS—skin cancer	0.000118	0.000208	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—KRAS—skin cancer	0.000116	0.000204	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—IL6—skin cancer	0.000114	0.0002	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TP53—skin cancer	0.000113	0.000198	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—BRAF—skin cancer	0.000113	0.000198	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—NRAS—skin cancer	0.000112	0.000196	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HRAS—skin cancer	0.000109	0.000191	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HRAS—skin cancer	0.000108	0.00019	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HRAS—skin cancer	0.000108	0.000189	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—HRAS—skin cancer	0.000106	0.000187	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—BRAF—skin cancer	0.000105	0.000184	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—IL6—skin cancer	0.000104	0.000183	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—IL6—skin cancer	0.000104	0.000182	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—KRAS—skin cancer	0.000103	0.000182	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—IL6—skin cancer	0.000103	0.000181	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—IL6—skin cancer	0.000102	0.000179	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTGS2—skin cancer	0.000101	0.000178	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HRAS—skin cancer	0.000101	0.000177	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HRAS—skin cancer	9.9e-05	0.000174	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NRAS—skin cancer	9.63e-05	0.000169	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—IL6—skin cancer	9.63e-05	0.000169	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—KRAS—skin cancer	9.61e-05	0.000169	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL6—skin cancer	9.48e-05	0.000166	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HRAS—skin cancer	8.79e-05	0.000154	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NRAS—skin cancer	8.78e-05	0.000154	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NRAS—skin cancer	8.7e-05	0.000153	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NRAS—skin cancer	8.59e-05	0.000151	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL6—skin cancer	8.42e-05	0.000148	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KRAS—skin cancer	8.29e-05	0.000145	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HRAS—skin cancer	8.17e-05	0.000143	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NRAS—skin cancer	8.12e-05	0.000143	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NRAS—skin cancer	8e-05	0.00014	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL6—skin cancer	7.82e-05	0.000137	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KRAS—skin cancer	7.55e-05	0.000133	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KRAS—skin cancer	7.49e-05	0.000131	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KRAS—skin cancer	7.39e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TP53—skin cancer	7.37e-05	0.000129	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NRAS—skin cancer	7.1e-05	0.000125	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HRAS—skin cancer	7.05e-05	0.000124	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KRAS—skin cancer	6.99e-05	0.000123	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KRAS—skin cancer	6.88e-05	0.000121	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL6—skin cancer	6.75e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TP53—skin cancer	6.71e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TP53—skin cancer	6.65e-05	0.000117	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NRAS—skin cancer	6.6e-05	0.000116	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TP53—skin cancer	6.57e-05	0.000115	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HRAS—skin cancer	6.42e-05	0.000113	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HRAS—skin cancer	6.36e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HRAS—skin cancer	6.28e-05	0.00011	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TP53—skin cancer	6.21e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL6—skin cancer	6.15e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TP53—skin cancer	6.12e-05	0.000107	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KRAS—skin cancer	6.11e-05	0.000107	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL6—skin cancer	6.09e-05	0.000107	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL6—skin cancer	6.01e-05	0.000105	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HRAS—skin cancer	5.94e-05	0.000104	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HRAS—skin cancer	5.85e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL6—skin cancer	5.69e-05	9.98e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KRAS—skin cancer	5.68e-05	9.96e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL6—skin cancer	5.6e-05	9.82e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TP53—skin cancer	5.43e-05	9.53e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HRAS—skin cancer	5.2e-05	9.12e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TP53—skin cancer	5.05e-05	8.86e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL6—skin cancer	4.97e-05	8.72e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HRAS—skin cancer	4.83e-05	8.47e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL6—skin cancer	4.62e-05	8.11e-05	CbGpPWpGaD
